A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

被引:47
作者
McClung, M. R. [1 ,2 ]
Bolognese, M. A. [3 ]
Brown, J. P. [4 ,5 ]
Reginster, J-Y [6 ,7 ]
Langdahl, B. L. [8 ]
Maddox, J. [9 ]
Shi, Y. [9 ]
Rojeski, M. [9 ]
Meisner, P. D. [10 ]
Grauer, A. [9 ]
机构
[1] Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA
[2] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia
[3] Bethesda Hlth Res Ctr, Bethesda, MD USA
[4] Laval Univ, Quebec City, PQ, Canada
[5] CHU Quebec CHUL Res Ctr, Quebec City, PQ, Canada
[6] Univ Liege, Liege, Belgium
[7] King Saud Univ, Riyadh, Saudi Arabia
[8] Aarhus Univ Hosp, Aarhus, Denmark
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
[10] UCB Phanna, Brussels, Belgium
关键词
Antiresorptive; Bone mineral density; Follow-on regimen; Osteoporosis; Romosozumab; POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY; PARATHYROID-HORMONE; DOUBLE-BLIND; DENOSUMAB; OSTEOPOROSIS; TERIPARATIDE; ALENDRONATE; PREVENTION; REDUCTION;
D O I
10.1007/s00198-020-05502-0
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accrued with romosozumab treatment and was well tolerated. Introduction Follow-on therapy with an antiresorptive agent is necessary to maintain the skeletal benefits of romosozumab therapy. We evaluated the use of zoledronate following romosozumab treatment. Methods This phase 2, dose-finding study enrolled postmenopausal women with low bone mineral density (BMD). Subjects who received various romosozumab doses or placebo from months 0-24 were rerandomized to denosumab (60 mg SC Q6M) or placebo for 12 months, followed by open-label romosozumab (210 mg QM) for 12 months. At month 48, subjects who had received active treatment for 48 months were assigned to no further active treatment and all other subjects were assigned to zoledronate 5 mg IV. Efficacy (BMD, P1NP, and beta-CTX) and safety were evaluated for 24 months, up to month 72. Results A total of 141 subjects entered the month 48-72 period, with 51 in the no further active treatment group and 90 in the zoledronate group. In subjects receiving no further active treatment, lumbar spine (LS) BMD decreased by 10.8% from months 48-72 but remained 4.2% above the original baseline. In subjects receiving zoledronate, LS BMD was maintained (percentage changes: - 0.8% from months 48-72; 12.8% from months 0-72). Similar patterns were observed for proximal femur BMD in both groups. With no further active treatment, P1NP and beta-CTX decreased but remained above baseline at month 72. Following zoledronate, P1NP and beta-CTX levels initially decreased but approached baseline by month 72. No new safety signals were observed. Conclusion A zoledronate follow-on regimen can maintain robust BMD gains achieved with romosozumab treatment.
引用
收藏
页码:2231 / 2241
页数:11
相关论文
共 35 条
[1]
Amgen Inc, 2019, EVENITY ROM AQQG US
[2]
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial [J].
Anastasilakis, Athanasios D. ;
Papapoulos, Socrates E. ;
Polyzos, Stergios A. ;
Appelman-Dijkstra, Natasha M. ;
Makras, Polyzois .
JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (12) :2220-2228
[3]
[Anonymous], 2017, TYML AB PRESCR INF
[4]
[Anonymous], 2019, EVENITY ROM EU SUMM
[5]
[Anonymous], 2012, FORT TER INJ PRESCR
[6]
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy -: A randomized controlled trial [J].
Ascott-Evans, BH ;
Guañabens, N ;
Kivinen, S ;
Stuckey, BGA ;
Magaril, CH ;
Vandormael, K ;
Stych, B ;
Melton, ME .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (07) :789-794
[7]
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures [J].
Austin, Matthew ;
Yang, Yu-Ching ;
Vittinghoff, Eric ;
Adami, Silvano ;
Boonen, Steven ;
Bauer, Douglas C. ;
Bianchi, Gerolamo ;
Bolognese, Michael A. ;
Christiansen, Claus ;
Eastell, Richard ;
Grauer, Andreas ;
Hawkins, Federico ;
Kendler, David L. ;
Oliveri, Beatriz ;
McClung, Michael R. ;
Reid, Ian R. ;
Siris, Ethel S. ;
Zanchetta, Jose ;
Zerbini, Cristiano A. F. ;
Libanati, Cesar ;
Cummings, Steven R. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :687-693
[8]
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis [J].
Bone, Henry G. ;
Cosman, Felicia ;
Miller, Paul D. ;
Williams, Gregory C. ;
Hattersley, Gary ;
Hu, Ming-yi ;
Fitzpatrick, Lorraine A. ;
Mitlak, Bruce ;
Papapoulos, Socrates ;
Rizzoli, Rene ;
Dore, Robin K. ;
Bilezikian, John P. ;
Saag, Kenneth G. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (08) :2949-2957
[9]
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials [J].
Bouxsein, Mary L. ;
Eastell, Richard ;
Lui, Li-Yung ;
Wu, Lucy A. ;
de Papp, Anne E. ;
Grauer, Andreas ;
Marin, Fernando ;
Cauley, Jane A. ;
Bauer, Douglas C. ;
Black, Dennis M. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (04) :632-642
[10]
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2016 [J].
Camacho, Pauline M. ;
Petak, Steven M. ;
Binkley, Neil ;
Clarke, Bart L. ;
Harris, Steven T. ;
Hurley, Daniel L. ;
Kleerekoper, Michael ;
Lewiecki, E. Michael ;
Miller, Paul D. ;
Narula, Harmeet S. ;
Pessah-Pollack, Rachel ;
Tangpricha, Vin ;
Wimalawansa, Sunil J. ;
Watts, Nelson B. .
ENDOCRINE PRACTICE, 2016, 22 :1-42